The glioma is one of the most aggressive tumors in humans, which is difficult to eradicate clinically. Therefore, we devised a porphyrin-based metal-organic frameworks (MOFs) crosslinking hyaluronic acid (HA) hydrogel nanocomposite through double-network (Cu-MOF-S-S-HA-Gel, CSSH-Gel), which is tumor responsive for enhanced gas therapy and sonodynamic therapy (SDT). Firstly, the hydrogels show extraordinary injectability and biocompatibility, which enables intratumor administration to circumvent the danger associated with surgery. The Cu-MOF-Cys and HA-Cys are interconnected through ether and disulfide bonds to establish a dual-network gel structure. The overexpressed glutathione (GSH) in tumor microenvironment (TME) reacts with disulfide bonds to release of the nanosensitizer (Cu-MOF). Subsequently, Cu-MOF generates reactive oxygen species (ROS) upon ultrasound irradiation for SDT, and releases L-cysteine(L-Cys) catalyzed by 3-mercapto pyruvate sulfotransferase (3-MST) to generate H 2 S for gas therapy. The CSSH-Gel obtained excellent synergistic anti-tumor effects (82.34 % inhibition ratio in vivo), which holds tremendous promise for the advancement of minimally invasive glioma therapies.
Bao-Xia Dong,She-Liang Qian,Fan-Yan Bu,Yi-Chen Wu,Li-Gang Feng,Yun-Lei Teng,Wen-Long Liu,Zong-Wei Li
Heterogeneous electrocatalysis provides better control of the chemical surroundings of the catalyst’s active site for improved performance, offers the possibility of overcoming drawbacks of deactivation caused by aggregation or dimerization in homogeneous condition, and permits the use of benign aqueous solutions. Employing metal–organic frameworks (MOFs) or covalent–organic frameworks (COFs) to support the active molecular catalyst of porphyrin for electrochemical conversion of CO2 to CO is a promising strategy. We have rationally introduced a 3D highly stable porphyrin-based MOF of PCN-222(Fe) into heterogeneous catalysis through the simple dip-coating method. The composite catalyst PCN-222(Fe)/C (mass ratio = 1:2) exhibited high catalytic performance for electrochemical conversion of CO2 to CO with 494 mV overpotential (where j = 1.2 mA cm–2) and maximum 91% FECO in a CO2-saturated 0.5 M KHCO3 aqueous solution, achieving a TOF of 0.336 site–1 s–1. The catalyst was found to retain its crystallinity and stability after 10 h of electrolysis at −0.60 V versus RHE (average FECO 80.4%; RHE, reversible hydrogen electrode), which generates 334 μmol of CO with the TOF of 0.012 s–1 (0.286 site–1 s–1). These results indicate that the PCN-222(Fe)/C has a substantial catalytic effect on the electrochemical reduction of CO2 due to the combination of the intrinsic activity of the porphyrin molecule, and the promising CO2 adsorption ability endowed by the conserved porosity, as well as the high conductivity of carbon black.
Dongping Rao,Luyan Meng,Xiuqin Sheng,Wenying Yu,Chuan-Fan Ding,Yinghua Yan
A hybrid material, M@C-Br@GMA@Glu, consisting of a porphyrin-based metal–organic framework-covalent organic framework (MOF@COF), has been meticulously synthesized using a post-synthetic modification approach. This advanced material has demonstrated exceptional effectiveness in glycopeptide enrichment, characterized by an impressively low detection limit (0.2 fmol μL−1), high selectivity (1 : 2000), and loading capacity for glycopeptides (100 mg g−1). In practical applications with complex biological samples, 210 glycopeptides associated with 87 glycoproteins from the serum of the healthy group, and 156 glycopeptides related to 85 glycoproteins from the serum of cervical cancer were identified after enrichment with M@C-Br@GMA@Glu. Subsequent genetic ontology analysis has elucidated the relationship between cervical cancer and glycosylation, focusing on biological processes such as complement activation, innate immune response mechanisms, and the structural dynamics of the extracellular matrix. The collective findings not only validate the material's proficiency in the sensitive and selective enrichment of glycopeptides, but also underscore its potential in biomarker discovery applications.
危险品化学品经营许可证（带存储）